BAGSVAERD, DENMARK--(Marketwire - October 31, 2012) -
* Sales grew 18% to 57.1 billion in Danish kroner and by 11% in local
currencies.
Sales of modern insulins increased by 21% (14% in local currencies).
Sales of Victoza(r) increased by 74% (64% in local currencies).
Sales in North America increased by 30% (19% in local currencies).
Sales in International Operations increased by 19% (16% in local
currencies).
* Reported gross margin improved by 1.5 percentage points to 81.9%.
* Reported operating profit increased by 34% to DKK 21,902 million.
Measured in local currencies, operating profit increased by 21%.
* Net profit increased by 26% to DKK 15,677 million. Earnings per share
(diluted) increased by 31% to DKK 28.32.
* The regulatory process for the new generation insulins, with the
intended brand names Tresiba(r) and Ryzodeg(r), continues to progress in the
major markets. In Japan, Tresiba(r) has now been approved and in Europe, CHMP
has issued positive opinions for Tresiba(r) and Ryzodeg(r). In the US, the FDA
has disclosed that the Advisory Committee meeting to discuss the new drug
applications on 8 November 2012 will focus on the benefits associated with
a lower risk of hypoglycaemia and the cardiovascular risk profiles of the
two products.
* For 2012, sales growth measured in local currencies is now expected to
be 10-12% (previously 9-12%), and operating profit growth measured in local
currencies is now expected to be 16-18% (previously around 15%).
* The preliminary outlook for 2013 indicates high single-digit sales and
operating profit growth, both measured in local currencies. The outlook
includes an expected positive sales contribution from Tresiba(r), primarily
in the US, EU and Japan, countered by an impact from the challenging
operating environment in major markets. In addition, the outlook for
operating profit reflects significant costs related to the expected launch
of Tresiba(r).
Lars Rebien Sørensen, president and CEO: "Continued strong sales of our
modern insulins and Victoza(r) have led to a robust financial performance in
the first nine months of 2012. The approval of Tresiba(r) in Japan and the
positive CHMP opinions in Europe for Tresiba(r) and Ryzodeg(r) constitute two
significant milestones in the process of bringing this new generation of
insulin to the market."
Company announcement No 70 / 2012:
http://hugin.info/2013/R/1653756/534186.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novo Nordisk A/S via Thomson Reuters ONE
[HUG#1653756]
